{"doi":"10.1111/josh.13404","title":"<scp>COVID</scp>‐19 Related Facilitators and Barriers to <scp>In‐Person</scp> Learning for Children With Intellectual and Development Disabilities: A <scp>Follow‐Up</scp>","abstract":"BACKGROUND: Students with intellectual and developmental disabilities (IDD) and the staff who support them were largely in-person during the 2021-2022 school year, despite their continued vulnerability to infection with SARS-CoV-2. This qualitative study aimed to understand continued perceptions of weekly SARS-CoV-2 screening testing of students and staff amidst increased availability of vaccinations. METHODS: Twenty-three focus groups were held with school staff and parents of children with IDD to examine the perceptions of COVID-19 during the 2021-2022 school year. Responses were analyzed using a directed thematic content analysis approach. RESULTS: Four principal themes were identified: strengths and opportunities of school- and district-level mitigation policies; experience at school with the return to in-person learning; facilitators and barriers to participation in SARS-CoV-2 screening testing; and perceptions of SARS-CoV-2 testing in light of vaccine availability. IMPLICATIONS FOR SCHOOL HEALTH POLICY, PRACTICE, AND EQUITY: Despite the increased availability of vaccines, school staff and families agreed that saliva-based SARS-CoV-2 screening testing helped increase comfort with in-person learning as long as the virus was present in the community. CONCLUSION: To keep children with IDD in school during the pandemic, families found SARS-CoV-2 screening testing important. Clearly communicating school policies and mitigation strategies facilitated peace of mind and confidence in the school district.","journal":"Journal of School Health","year":2023,"id":412944,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9589,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04565509"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":244582,"name":"Ann Marie Schmidt","orcid":"0000-0001-8902-070X","position":1,"is_corresponding":false},{"id":756719,"name":"Nikole Lobb Dougherty","orcid":null,"position":2,"is_corresponding":false},{"id":1033012,"name":"Liz Rolf","orcid":"0000-0003-4900-3133","position":3,"is_corresponding":false},{"id":435559,"name":"Jason G. Newland","orcid":"0000-0001-9979-7993","position":4,"is_corresponding":false},{"id":756724,"name":"Nancy B. Mueller","orcid":null,"position":5,"is_corresponding":false},{"id":962008,"name":"for the COMPASS‐T Study Group","orcid":null,"position":6,"is_corresponding":false},{"id":756055,"name":"Liz E. Vestal","orcid":"0000-0002-3441-8929","position":0,"is_corresponding":true}],"reference_count":21,"raw_metadata":null,"created_at":"2026-07-19T01:21:53.745400Z","pmid":"37853427","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}